JESSICA NUTT: Open Payments
NPI 1477935385 · PARAGOULD, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$983 in 47 payments from 9 companies in 2025. Trend: 2023 $64 · 2024 $2,204 · 2025 $983
Food & beverage: $983
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $512 |
| Novartis Pharmaceuticals Corporation | 11 | $202 |
| Biogen, Inc. | 3 | $68 |
| SK Life Science, Inc. | 2 | $54 |
| Genentech USA, Inc. | 3 | $52 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Novo Nordisk Inc | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $19 |
Products named: QULIPTA, KESIMPTA, UBRELVY, ZURZUVAE, VRAYLAR, Ocrevus Zunovo, FARXIGA, GEMTESA.
Industry payments across AR — which companies pay providers there.
